[18] [19] Clinic data also note it does not disrupt hormonal pathways targeted by finasteride, making it attractive for users sensitive to hormone-based treatments
Other reported mechanisms include activation of FAK-paxillin complexes (which help cells migrate and attach to surfaces during wound healing), JAK-2 signaling, and ERK1/2 pathway activity (Sikiric et al., Current Neuropharmacology, 2016
Layering a second incretin agonist on top of Retatrutide does not add a new mechanism it doubles down on receptors the triple agonist already saturates, so the predictable result is additive gastrointestinal load and, if either agent has glucose-lowering partners on board, additive hypoglycemia risk
This helps in softening fine lines, reducing age spots, and improving skin elasticity
Neither medication should be used during pregnancy or breastfeeding